Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Chemoradiotherapy in Cervical Cancer
NCT03738228Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in Cervical Cancer (CC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Immune Response (TCRB clonal expansion) at Day 42. Started Jan 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03738228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738228.